Fenoksipropazin

{{Drugbox-lat | IUPAC_name = (1-metil-2-fenoksi-etil)hidrazin | image = Phenoxypropazine skeletal.svg | width = 200px | image2 = | width2 =

| tradename = | pregnancy_category = | legal_status = Rx-only | routes_of_administration = Oralno

| bioavailability = | metabolism = | elimination_half-life = | excretion =

| C=9 | H=14 | N=2 | O=1 | molecular_weight = 166,22 -{g/mol} | smiles = | StdInChI_Ref = ^Y | StdInChI = | StdInChIKey_Ref = ^Y | StdInChIKey = }} Fenoksipropazin (prodajno ime Drazin) je ireverzibilni i neselektivni inhibitor monoaminoksidaze (MAOI) iz hidrazinske hemijske klase. On je uveden u upotrebu kao antidepresiv 1961, ali je naknadno povućen sa tržišta 1966. zbog moguće pojave hepatotoksičnosti.^[1]^[2]^[3]^[4]^[5]

Vidi još[уреди]

↑ LEAHY MR, ROSE JT, PLOWMAN R (1963). „A preliminary study of phenoxypropazine in the treatment of depression”. The American Journal of Psychiatry. 119: 986—7. PMID 13928824.
↑ IMLAH NW (1963). „Preliminary report on phenoxypropazine”. The American Journal of Psychiatry. 119: 1091—2. PMID 13956423.
↑ ROSE JT, LEAHY MR, PLOWMAN R (1963). „A comparison of phenoxypropazine and amitriptyline in depression”. The American Journal of Psychiatry. 120: 393—5. PMID 14069469.
↑ ROSE JT (1964). „Phenoxypropazine and chlordiazepoxide in depression”. The American Journal of Psychiatry. 120: 899—900. PMID 14129290.
↑ MCWHINNEY IR, MORRELL DC (1965). „Treatment of mild endogenous depression with a monoamine oxidase inhibitor: a controlled trial in general practice”. The Journal of the College of General Practitioners. 9: 95—9. PMC 1878242 . PMID 14254271.